Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Gynaecol Oncol ; 35(3): 224-9, 2014.
Article in English | MEDLINE | ID: mdl-24984532

ABSTRACT

PURPOSE: To investigate the effectiveness of platinum-based combination chemotherapy as second-line chemotherapy for patients with advanced or recurrent endometrial cancer treated initially by platinum-based combination chemotherapy. MATERIALS AND METHODS: Subjects were patients who had received platinum-based combination chemotherapy as second-line chemotherapy: 56 patients with recurrent disease who had previously received postoperative adjuvant platinum-based combination chemotherapy (Category 1) and 21 patients who had received first-line chemotherapy but not adjuvant chemotherapy for advanced or recurrent disease (Category 2). Patients' records were searched for the response to second-line chemotherapy and survival, particularly in relation to the platinum-free interval (PFI). RESULTS: APFI over 12 months was a predictor of response (64.7%) and overall survival time (23 months) in Category 1 patients. A PFI of less than three months was a negative predictor of response (0%) and overall survival (nine months) in Category 2 patients. CONCLUSION: Platinum-based combination chemotherapy appears to be effective as second-line chemotherapy for endometrial cancer if the PFI is sufficiently long.


Subject(s)
Endometrial Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Adult , Aged , Endometrial Neoplasms/mortality , Female , Humans , Middle Aged
2.
Eur J Gynaecol Oncol ; 34(4): 291-5, 2013.
Article in English | MEDLINE | ID: mdl-24020131

ABSTRACT

PURPOSE: To investigate treatment outcomes of uterine carcinosarcoma (CS) patients who underwent complete surgical resection of all visible disease and platinum-based adjuvant chemotherapy (multimodal therapy). MATERIALS AND METHODS: The authors reviewed 127 uterine CS patients treated at this institution from 1990 to 2010. They operated 123 patients in clinical Stages 1-3, 97 of which underwent complete resection and systemic lymphadenectomy. RESULTS: A total of 97 patients (FIGO 2008: Stage 1 in 50 patients, Stage 2 in six, Stage 3 in 37, and Stage 4 in four) underwent surgical staging, 74 of which were administered five cycles (median) of platinum-based adjuvant chemotherapy. The median overall survival (OS) associated with multimodal therapy 50.6 months compared with 34.9 months incomplete multimodal therapy. After multimodal treatment, 32.9% (32/97) patients showed recurrence (24/32 hematogenous). CONCLUSION: Multimodal therapy increased survival among uterine CS patients, but the recurrence rate remained high. Further consideration of treatment options for uterine CS is required.


Subject(s)
Carcinosarcoma/therapy , Uterine Neoplasms/therapy , Adult , Aged , Carcinosarcoma/mortality , Carcinosarcoma/pathology , Combined Modality Therapy , Female , Humans , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Prognosis , Uterine Neoplasms/mortality , Uterine Neoplasms/pathology
3.
Eur J Gynaecol Oncol ; 32(6): 647-50, 2011.
Article in English | MEDLINE | ID: mdl-22335027

ABSTRACT

PURPOSE: To investigate clinical outcomes with respect to the effectiveness of chemotherapy in the treatment of uterine leiomyosarcoma. METHODS: Study subjects were 18 patients with uterine leiomyosarcoma treated surgically at our hospital between February 1986 and December 2007. A chemotherapy regimen that combined ifosfamide, epirubicine, and cisplatin (IEP) was used as the main first-line chemotherapy. RESULTS: FIGO disease stages were as follows: Stage I (n = 11), Stage II (n = 1), Stage III (n = 3), Stage IV (n = 3). Five-year overall survival of patients with Stage I-III disease was 65.3% (95% CI: 46.1-92.4%). None of patients with Stage IV disease survived for more than two years. Of seven patients who suffered advanced or recurrent disease, six received IEP; the response rate was 50%, one complete response and two partial responses. CONCLUSIONS: The combination of surgery and chemotherapy seems to be an acceptable treatment for uterine leiomyosarcoma. IEP may be an active regimen for this aggressive disease.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leiomyosarcoma/drug therapy , Uterine Neoplasms/drug therapy , Adult , Aged , Female , Humans , Leiomyosarcoma/mortality , Leiomyosarcoma/pathology , Middle Aged , Neoplasm Staging , Uterine Neoplasms/mortality , Uterine Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...